TrialRMD open2021

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.